Thomas J. Jensen
Soborg, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.
Journal: Journal of the American College of Cardiology
Published: July 19, 2024
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
Journal: European heart journal
Published: April 09, 2024
Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
Journal: Journal of the American College of Cardiology
Published: March 22, 2024
Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis.
Journal: Diabetes, obesity & metabolism
Published: August 03, 2023
Volume-Weighted Unipolar Voltage Predicts Heart Failure Mortality in Patients With Dilated Cardiomyopathy and Ventricular Arrhythmias.
Journal: JACC. Clinical electrophysiology
Published: June 03, 2022
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
Journal: Diabetes care
Published: March 03, 2020
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Journal: Diabetes care
Published: March 30, 2016
Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
Journal: Expert opinion on drug safety
Published: February 06, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026